Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 806.6 g/mol |
---|---|
Molecular Formula | C20H28N12O9PPt+ |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 1 |
Exact Mass | 806.148777 g/mol |
Monoisotopic Mass | 806.148777 g/mol |
Topological Polar Surface Area | 274 A^2 |
Heavy Atom Count | 43 |
Formal Charge | 1 |
Complexity | 1050 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 6 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 4 |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9601
Submission : 1992-03-26
Status : Active
Type : II
Certificate Number : CEP 2005-253 - Rev 02
Issue Date : 2025-01-22
Type : Chemical
Substance Number : 599
Status : Valid
Registration Number : 222MF10106
Registrant's Address : 435 Devon Park Drive, Suite 400, Wayne, Pennsylvania 19087 USA
Initial Date of Registration : 2010-03-19
Latest Date of Registration :
NDC Package Code : 49812-0009
Start Marketing Date : 1985-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-21
Pay. Date : 2014-03-10
DMF Number : 28046
Submission : 2014-03-09
Status : Active
Type : II
Certificate Number : R1-CEP 2012-012 - Rev 00
Issue Date : 2018-06-01
Type : Chemical
Substance Number : 599
Status : Valid
NDC Package Code : 72659-864
Start Marketing Date : 2017-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7017
Submission : 1987-06-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23985
Submission : 2010-05-22
Status : Active
Type : II
Certificate Number : R1-CEP 2010-122 - Rev 02
Issue Date : 2021-09-16
Type : Chemical
Substance Number : 599
Status : Valid
NDC Package Code : 67184-0010
Start Marketing Date : 2023-11-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4098
Submission : 1981-03-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4824
Submission : 1983-03-03
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 2015-08-18
Application Number : 206774
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 1999-07-16
Application Number : 74735
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 2017-03-17
Application Number : 207323
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 2000-11-07
Application Number : 75036
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : Yes
TE Code :
Brand Name : PLATINOL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 10MG/VIAL
Approval Date : 1982-01-01
Application Number : 18057
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 50MG/VIAL
Approval Date : 1982-01-01
Application Number : 18057
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : PLATINOL-AQ
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 0.5MG/ML
Approval Date : 1984-07-18
Application Number : 18057
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : Yes
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 1988-11-08
Application Number : 18057
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AP
RLD : No
TE Code : AP
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 2000-05-16
Application Number : 74656
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : CISPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 1MG/ML
Approval Date : 2000-05-16
Application Number : 74814
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cisplatin Accord
Dosage Form : Inf Conc
Dosage Strength : 25mg/25ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Cisplatin The Fresenius Kabi
Dosage Form : Concentrate to the infusion fluid, resolution
Dosage Strength : 1 mg/ml
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Cisplatin Hospira
Dosage Form : CONCENTRATE FOR SOLUTION FOR INFUSION
Dosage Strength : 1 MG / ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Cisplatin
Dosage Form : Cisplatin 100Mg 100Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 100 mg 100 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Cisplatin
Dosage Form : Cisplatin 50Mg 50Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 50 mg 50 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Cisplatin Hospira
Dosage Form : Concentrate to the infusion fluid
Dosage Strength : 1 mg/ml
Packaging : Hood glass of dark glass with plastic Sheaths
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cisplatin Sandoz
Dosage Form : Inf Conc
Dosage Strength : 10mg/20ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cisplatin Sandoz
Dosage Form : Inf Conc
Dosage Strength : 50mg/100ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : Cisplatin
Dosage Form : Cisplatin 100Mg 100Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 100 mg 100 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Ready Platamine
Dosage Form : Cisplatin 10Mg 20Ml 1 Units Parenteral Use
Dosage Strength : 1 vial EV 10 mg 20 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Mannogem 2080 exhibits excellent flow, disintegration and compression properties.
Dosage Form : Orodispersible Tablet
Grade : Oral
Dosage Form : Orodispersible Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Company : Accord Healthca
Cisplatin
Drug Cost (USD) : 6,696
Year : 2023
Prescribers : 60
Prescriptions : 116
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Apotex Corp
Cisplatin
Drug Cost (USD) : 2,045
Year : 2023
Prescribers : 17
Prescriptions : 24
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Cisplatin
Drug Cost (USD) : 6,154
Year : 2023
Prescribers : 63
Prescriptions : 131
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bluepoint Labor
Cisplatin
Drug Cost (USD) : 7,445
Year : 2023
Prescribers : 58
Prescriptions : 118
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Teva Parenteral
Cisplatin
Drug Cost (USD) : 4,499
Year : 2023
Prescribers : 45
Prescriptions : 86
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : West-Ward/Hikma
Cisplatin
Drug Cost (USD) : 1,299
Year : 2023
Prescribers : 27
Prescriptions : 37
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bluepoint Labor
Cisplatin
Drug Cost (USD) : 13,775
Year : 2022
Prescribers : 73
Prescriptions : 186
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Accord Healthca
Cisplatin
Drug Cost (USD) : 16,342
Year : 2022
Prescribers : 101
Prescriptions : 274
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : App/Fresenius K
Cisplatin
Drug Cost (USD) : 3,792
Year : 2022
Prescribers : 33
Prescriptions : 70
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : West-Ward/Hikma
Cisplatin
Drug Cost (USD) : 793
Year : 2022
Prescribers :
Prescriptions : 24
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Reply
22 Jul 2025
Reply
02 Jul 2025
Reply
18 Oct 2024
Reply
01 Aug 2024
Reply
10 Jan 2022
Reply
04 Nov 2021
Reply
11 Aug 2021
Reply
17 Jul 2021
Reply
11 Mar 2019
Reply
05 Sep 2022
Reply
08 Jul 2021
Reply
17 Jun 2021
Reply
17 May 2021
Reply
17 Apr 2021
Reply
26 Mar 2021
Reply
03 Mar 2021
Reply
30 Jul 2020
Reply
11 May 2020
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
70
PharmaCompass offers a list of Cisplatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cisplatin manufacturer or Cisplatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cisplatin manufacturer or Cisplatin supplier.
PharmaCompass also assists you with knowing the Cisplatin API Price utilized in the formulation of products. Cisplatin API Price is not always fixed or binding as the Cisplatin Price is obtained through a variety of data sources. The Cisplatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cisplatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cisplatin, including repackagers and relabelers. The FDA regulates Cisplatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cisplatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cisplatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cisplatin supplier is an individual or a company that provides Cisplatin active pharmaceutical ingredient (API) or Cisplatin finished formulations upon request. The Cisplatin suppliers may include Cisplatin API manufacturers, exporters, distributors and traders.
click here to find a list of Cisplatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cisplatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Cisplatin active pharmaceutical ingredient (API) in detail. Different forms of Cisplatin DMFs exist exist since differing nations have different regulations, such as Cisplatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cisplatin DMF submitted to regulatory agencies in the US is known as a USDMF. Cisplatin USDMF includes data on Cisplatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cisplatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cisplatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cisplatin Drug Master File in Japan (Cisplatin JDMF) empowers Cisplatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cisplatin JDMF during the approval evaluation for pharmaceutical products. At the time of Cisplatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cisplatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cisplatin Drug Master File in Korea (Cisplatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cisplatin. The MFDS reviews the Cisplatin KDMF as part of the drug registration process and uses the information provided in the Cisplatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cisplatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cisplatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cisplatin suppliers with KDMF on PharmaCompass.
A Cisplatin CEP of the European Pharmacopoeia monograph is often referred to as a Cisplatin Certificate of Suitability (COS). The purpose of a Cisplatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cisplatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cisplatin to their clients by showing that a Cisplatin CEP has been issued for it. The manufacturer submits a Cisplatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cisplatin CEP holder for the record. Additionally, the data presented in the Cisplatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cisplatin DMF.
A Cisplatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cisplatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cisplatin suppliers with CEP (COS) on PharmaCompass.
A Cisplatin written confirmation (Cisplatin WC) is an official document issued by a regulatory agency to a Cisplatin manufacturer, verifying that the manufacturing facility of a Cisplatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cisplatin APIs or Cisplatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Cisplatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Cisplatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cisplatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cisplatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cisplatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cisplatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cisplatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cisplatin suppliers with NDC on PharmaCompass.
Cisplatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cisplatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cisplatin GMP manufacturer or Cisplatin GMP API supplier for your needs.
A Cisplatin CoA (Certificate of Analysis) is a formal document that attests to Cisplatin's compliance with Cisplatin specifications and serves as a tool for batch-level quality control.
Cisplatin CoA mostly includes findings from lab analyses of a specific batch. For each Cisplatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cisplatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Cisplatin EP), Cisplatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cisplatin USP).